News
Portfolio Company News
- February 01, 2012
Ablynx Receives Another Milestone as Boehringer Ingelheim Selects Nanobody® Candidate for Pre-Clinical Development
- January 31, 2012
Wills Hughes-Wilson appointed Vice President Government Affairs & Policy - Swedish Orphan Biovitrum
- January 31, 2012
AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012
- January 20, 2012
Novel Immune Regulation Mechanism Involving Natural Killer Cells Described and Published in "Science" Magazine by a Key Academic Partner of Innate Pharma
- January 19, 2012
Pathwork Diagnostics: Cancer Patients Experience Increased Survival Time After Pathwork Tissue of Origin Test
- January 13, 2012
Sobi Signs Global Licensing Agreement for Novel Neonatology Treatment from Only for Children Pharmaceuticals
- January 10, 2012
Ablynx is Granted Extended GMP Certificate for New GMP Unit
- January 09, 2012
Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
- January 09, 2012
Pathwork® Tissue of Origin Test Cost-Effective
For Increasing Cancer Patient Survival
- January 06, 2012
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
- January 05, 2012
GSK Exercises Option to License ChemoCentryx’s CCR1 Inhibitor, CCX354, for the Treatment of Rheumatoid Arthritis
- January 04, 2012
BioWorld Today: News to Note - Astex Therapeutics - January 04, 2012
Veloxis Pharmaceuticals Announces Initiation of STRATO Study of LCP-Tacro™ in Kidney Transplant Recipients Experiencing Tremors
- December 14, 2011
Medical Device Daily: Product Briefs - Vertiflex - December 14, 2011
Ablynx Adds Another Key Patent to its Expanding Patent Estate Around Half-Life Extension
- December 14, 2011
Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias
- December 13, 2011
Ablynx Initiates Phase I Study with ALX-0171 for the Treatment of Respiratory Synctial Virus (RSV)
- December 13, 2011
Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
- December 13, 2011
Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference
- December 12, 2011
Ablynx and Merck Serono Select a Novel Nanobody Candidate, ALX-0761, for Pre-clinical Dvelopment
< Previous
